A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation is a phase 3 interventional study registered as NCT06952803, led by AstraZeneca with Parexel, and recruiting on the registry. Official title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02). Planned enrolment is 700 participants (estimated). The study started in 2025-08-06 and primary completion is expected in 2033-03-31. No results have been posted on ClinicalTrials.gov.